[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trastuzumab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trastuzumab":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,88],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100625767",false,"NCT07426913","Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab","Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2","Inclusion Criteria:\n\n* 18 years of age or older\n* Able to speak and read in English\n* Actively receiving Trastuzumab or an anthracycline-based treatment\n* Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab.\n* Diagnosed with stages 0-III Breast Cancer\n\nExclusion Criteria:\n\n\\- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)","FEMALE","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).",[25,26,27,28],"Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer","Virtual Reality","Trastuzumab",[30,31,32,33,34,35],"virtual reality","breast cancer","antracyclines","trastuzumab","VCU","Virginia Commonwealth University","RECRUITING","2026-07-01",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-05-20",{"date":44,"type":19},"2027-02-28",{"name":35,"class":46},"OTHER",{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":73,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100595293","NCT07030569","RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","RADIOSPHER2","Inclusion Criteria:\n\n* Patients with metastatic breast cancer underwent a liver, lung, pleural or bone biopsy in the metastatic setting, performed from 01Jan2005 to 01Jan2024.\n\nExclusion Criteria:\n\n* Not available imaging (CT scan and\u002For PET-FdG scan) in the three months before the biopsy or before the last previous treatment interruption;\n* Unknown HER2 status;\n* Node, soft tissue or other visceral as biopsy site.","ALL",{"count":55,"type":19},500,"OBSERVATIONAL","RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.",[59,60,61,62,63,64,25,65,66,28,67,68,69,70,71,72],"Radiomic","Radiomics","Breast Cancer Metastatic","Breast Cancer Stage IV","Breast Carcinoma","Breast Neoplasms","Breast Cancer With Bone Metastasis","Breast Cancer With Metastatic Bone Disease","HER2","HER2 + Breast Cancer","HER2 Positive Breast Carcinoma","HER2-positive Breast Cancer","Her2\u002FNeu Positive Advanced Solid Tumors","HER2\u002FNeu-positive Breast Cancer",[60,74,75,76,77],"HER2 expression","Trastuzumab Deruxtecan","Pathomics","HER2 heterogeneity","2025-06-12",{"date":80,"type":40},"2025-06-22",{"date":82,"type":40},"2024-02-01",{"date":84,"type":19},"2027-01-01",{"name":86,"class":46},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",1,{"id":89,"slug":4,"hasResults":10,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":20,"phases":97,"briefSummary":98,"conditions":99,"keywords":107,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":87},"100531268","NCT06197581","Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer","RADIOCOM","Inclusion Criteria:\n\nECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to receive radiotherapy according to guidelines. Radiotherapy target volume included chest wall\u002Fbreast with or without lymph node regions.\n\nNeed to receive one of the following therapies according to guidelines, capetabine, CDK4\u002F6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors.\n\nExclusion Criteria:\n\nMale breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone during and\u002For after radiotherapy. With severe other disease.","70 Years",{"count":96,"type":19},148,[22],"Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4\u002F6 inhibitors, PARP inhibitors, capecitabine and PD1 inhibitors have greatly improved the prognosis of breast cancer and has become the standard treatment for specific populations. A considerable number of patients require both radiotherapy and maintenance systemic therapy. However, it is not clear whether systemic therapy should be synchronized or suspended in radiotherapy，despite that previous basic research shows that some molecular drug therapy and radiotherapy has a clear synergy mechanism. There is an agent need for a definite evidence to evaluate the safety of synchronous treatment, to support clinical diagnosis and treatment and the next step of comprehensive treatment. The implementation of the new radiotherapy technology represented by IMRT takes into account the prescription dose homogenization and the minimization of normal tissue dosage, which provides a certain basis for the combination therapy. Based on the above conditions, this study intends to enroll patients between 18 and 70 years old with chest wall \u002F breast ± lymphatic drainage area and requiring capecitabine, CDK 4\u002F 6 inhibitor, HER2 targeted therapy or immunotherapy. Radiation and novel systemic therapies would be delivered concurrently. The study aimed at evaluating the safety of combined treatments.",[100,101,102,103,104,28,105,106],"Breast Cancer, Familial Male","Radiotherapy; Complications","Chemotherapeutic Toxicity","Immune Checkpoint Inhibitor","CDK4\u002F6 Inhibitor","Pertuzumab","PARP Inhibitor",[25,108,109,110,28,105,111,112,113],"Radiotherapy","Adverse events","Capecitabine","Immune checkpoint inhibitor","CDK4\u002F6 inhibitor","PARP inhibitor","2024-08-19",{"date":116,"type":40},"2024-08-21",{"date":118,"type":40},"2024-01-12",{"date":120,"type":19},"2027-01-15",{"name":122,"class":46},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",""]